
BiomX Inc. (PHGE) Stock Forecast & Price Target
BiomX Inc. (PHGE) Analyst Ratings
Bulls say
BiomX Inc. is positioned positively due to its innovative phage-based technology aimed at addressing unmet medical needs in chronic diseases, such as cystic fibrosis and diabetic foot osteomyelitis. The company’s strategic trial design for the BX211 product candidate, which could significantly improve disease severity, creates a favorable outlook for its phage therapies. Furthermore, potential for increased market penetration, expansion into additional indications, and growth in international markets underpins an optimistic valuation trajectory for BiomX.
Bears say
BiomX Inc. faces significant headwinds in achieving commercial success for its therapeutic phage products due to potential failed or inconclusive clinical trials that could jeopardize ongoing development efforts. The financial outlook is further complicated by the company’s challenges in securing adequate funding, which may hinder the advancement of their drug candidates through the necessary development pathways. Additionally, the risk of dilutive capital raises may negatively impact shareholder value, contributing to a negative sentiment surrounding the stock.
This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.
BiomX Inc. (PHGE) Analyst Forecast & Price Prediction
Start investing in BiomX Inc. (PHGE)
Order type
Buy in
Order amount
Est. shares
0 shares